Harrison et al. ([@B1]) analyzed pancreatic β-cell function in drug-naïve patients with type 2 diabetes before and 42 months after treatment with insulin plus metformin or a combination of metformin, glyburide, and pioglitazone. The pretreatment evaluation was not exactly "before" the treatment. It was carried out after 3 months of the run-in period with insulin plus metformin therapy for all participants. The study is well designed, the analysis is appropriate, and the data are straightforward except for two potential drawbacks: absence of a wash-out period prior to the final meal test and failure to pay attention to alteration in insulin sensitivity caused by the treatments. The authors withheld hypoglycemic agents only for 24 h before the final meal test. This is inappropriate to evaluate the disease-modifying effect of the two treatment modalities. Nevertheless, the title says "preservation of β-cell function," i.e., presence of a disease-modifying effect. Glyburide is especially problematic: the insulinotropic effect of glyburide does not fade away within 24 h ([@B2]). Therefore, it is impossible to distinguish a direct insulinotropic effect of the drug and the disease-modifying effect of it with this protocol. It was absolutely needed to stop glyburide at least for a few days, ideally for a week, before the "post-treatment" meal test in order to identify the β-cell preserving effect, if any. Of course, the final meal test should have been carried out after the same wash-out period in the insulin- and metformin-treated group for the fair comparison of the two treatment modalities. The second point is also profoundly important. Pioglitazone's insulin-sensitizing effect may last longer than 24 h ([@B3]). In addition, glucose lowering by any means restores insulin sensitivity of the body to some extent ([@B4]). Therefore, β-cell function should have been evaluated with alteration of insulin sensitivity taken into consideration, especially after an appropriate wash-out period for pioglitazone. The authors found no change in plasma C-peptide or C-peptide--to--glucose ratio by the two treatments and took the finding as evidence for "preserved β-cell function" ([@B1]). However, it may imply improved or worsened β-cell function if insulin sensitivity had gone up or down, respectively. The most popular approach to obviate this problem is calculating oral disposition index ([@B5]). At least, the authors should have commented on the above-mentioned two issues as limitations of the study. The title might be misleading in that it gives an impression that the disease-modifying effect, which is of paramount importance, was successfully achieved by the conventional pharmacological therapies.
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